other material
confidence high
sentiment neutral
materiality 0.75
CytomX closes public offering of ~47M shares/warrants, net proceeds ~$234.4M for pipeline
CytomX Therapeutics, Inc.
- Sold 45,990,567 shares at $5.30 and pre-funded warrants for 1,179,245 shares at $5.29999 each.
- Underwriters granted 30-day option to purchase up to 7,075,471 additional shares at the offering price.
- Net proceeds estimated at approximately $234.4 million after underwriting discounts and expenses.
- Proceeds to fund continued development of Varseta-M and other pipeline programs, plus general corporate purposes.
- Offering closed on March 19, 2026 under an underwriting agreement dated March 17, 2026.